NCT05225389View on ClinicalTrials.gov

Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of CT1812 in Healthy Adult Male Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

December 31, 2021

Primary Completion Date

January 17, 2022

Study Completion Date

January 24, 2022

Conditions
Alzheimer Disease
Interventions
DRUG

300 mg [C14] CT1812

Single dose of 300 mg CT1812 with microtracer dose of \[C14\]

Trial Locations (1)

68502

Celerion, Lincoln

Sponsors
All Listed Sponsors
collaborator

National Institute on Aging (NIA)

NIH

lead

Cognition Therapeutics

INDUSTRY

NCT05225389 - Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of CT1812 in Healthy Adult Male Subjects | Biotech Hunter | Biotech Hunter